EPIDEMOILOGY, DIAGNOSIS, AND TREATMENT OF HIV-ASSOCIATED NON-HODGKIN LYMPHPOMAS

The objective of the study was to analyze clinical, immunological and morphological features of malignant non-Hodgkin lymphpomas (MNHL) in HIV-infected patients, evaluate the options and the results of the treatment for the patients in oncohematological hospital environment. Materials and methods. The study evaluated the data from Original Medical Records of 185 HIVinfected patients (mean age 36–40 years) with MNHL that was detected during the period from 1994 to 2017. The results of clinical, laboratory, morphological and immunohistochemical methods used for the study in HIV-infected patients with MNHL were represented. Results. During the period from 1994 to 2017, increasing in the number of HIV-infected patients with MNL, mean age of which was less than 40 years, had been marked. Duration of HIV-infection up to the time of detection the MNHL was 7 years but in 23% of cases the HIV-infection and tumor disease were diagnosed at the same time. Low number of CD4 lymphocyte cells (132 cells/μL) and high number of RNA HIV (more than 550 000 copies/μL) were detected in the blood of the patients. The following distribution was among morphological types of MNHL: diffuse large B-cell lymphoma (DLBCL) — 42%, Burkitt's lymphomas — 32%, plasmablastic lymphomas — 26%. Clinical lymphomas with the extranodal manifestations accompanied with large quantity of complications and opportunistic infections directly resulted from immunosuppression severity (p<0,05) were predominant (76%). Evaluation of combined chemoimmunotherapy effectiveness in HIV-infected patients and in the patients with MNHL showed comparable results in contrast with the population of seronegative HIV-infected patients under using standard polychemotherapy regimens with rituximab, antiretroviral therapy, prevention of infectious complications and immune reconstitution syndrome. Conclusion. Malignant non-Hodgkin lymphpomas represent the group of oncological diseases, which is predominant in HIV-infected patients. These diseases require team approach in early detection, current treatment, prevention of complications in the multidisciplinary team that will significantly improve disease outcome.

1. Centers for Disease Control (CDC): Update on acquired immune deficiency syndrome (AIDS): United States. Morb. Mortal. Wkly Rep. (MMWR), 1982, Vol. 31, pp. 507–508, 513–514.

2. URL: https://spid-vich-zppp.ru/statistika/ofitsialnaya-statistika-vich-spid-rf-2016.html

3. Belyakov N.A., Rassokhin V.V., Leonova O.N., Stepanova E.V., Bobreshova A.S. Integral assessment of the severity of the patient’s condition against the background of comorbidity in HIV infection. HIV Infection and Immunosuppressive Disorders, 2017, Vol. 9, No. 3, pp. 47–53 (in Russ.).

4. Belyakov N.A., Rassokhin V.V., Trofimova T.N. Comorbid and severe forms of HIV infection in Russia. HIV infection and Immunosuppressive Disorders, 2015, Vol. 8, No. 3, pp. 9–21 (In Russ.).

5. Bobkova M. R. Drug resistance of HIV. Moscow: Chelovek, 2014, 287 p. (In Russ.).

6. Engels E.A., Biggar R.J., Hall H.I. et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer, 2008, Vol. 123 (1), pp. 187–194.

7. Engels E.A., Pfeiffer R.M., Goedert J.J. et al. HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS, 2006, Vol. 20, pp. 1645–1654.

8. Shiels M.S., Koritzinsky E.H., Clarke C.A. et al. Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol. Biomarkers Prev., 2014, Vol. 23 (2), pp. 274–281.

9. Biggar R.J., Jaffe E.S., Goedert J.J. et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood, 2006, Vol. 108 (12), pp. 3786–3791.

10. Cheson B.D. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol., 2014, Vol. 32 (27), pp. 3059–3068.

11. Shiels M., Pfeiffer R., Gail M. et al. Cancer burden in the HIV-Infected population in the United States. J. Natl. Cancer Inst., 2011, Vol. 103, pp. 753–762.

12. Simard E.P., Pfeiffer R.M., Engels E.A. Spectrum of cancer risk late after AIDS onset in the United States. Arch. Intern. Med., 2010, Vol. 170 (15), pp. 1337–1345.

13. Gopal S., Achenbach C.J., Yanik E.L., Dittmer D.P., Eron J.J., Engels E.A. Moving forward in HIV-associated cancer. JCO, 2014, Vol. 32, No. 9, pp. 876–880.

14. Gopal S., Patel M.R., Yanik E.L. et al. Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS, 2013, Vol. 27, pp. 2365–2373.

15. Grulich A.E., van Leeuwen M.T., Falster M.O. et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet, 2007, Vol. 370 (9581), pp. 59–67.

16. da Silva S.R., de Oliveira D.E. HIV, EBV and KSHV: Viral cooperation in the pathogenesis of human malignancies. Cancer Lett., 2011, Vol. 305 (2), pp. 175–185.

17. Immunohistochemical methods: guidance / George L. Kumar, Lars Rudbeck: Dako; trans. with English, eds. G.A.Frank and P.G. Malkov. Moscow: RMAPO, 2011, 224 p. (In Russ.).

18. Borovikov V.P. Popular introduction to modern data analysis in STATISTICA system: Methodology and technologies of modern data analysis. Moscow: Hotline-Telecom, 2013, 288 p. (In Russ.).

19. Plavinskiy S.L. Introduction to biostatistics for physicians. Moscow: Astrel, 2011, 584 p. (In Russ.).

20. Rebrova O.V. Statistical analysis of medical data with the help of a package of programs Statistics. Moscow: Media Sphere, 2002, 380 p. (In Russ.).

21. Woman, child and HIV. Eds. N.A.Belyakova, N.Yu.Rakhmanina, A.G.Rakhmanova. Saint-Petersburg: Baltic medical education center, 2012, pp. 17–44 (In Russ.).

22. Trofimova T.N., Belyakov N.A., Rassokhin V.V. Radiology and HIV infection. Saint-Petersburg: Baltic medical education center, 2017, 370 p. (In Russ.).

23. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Under the hands. I.V.Poddubnaya, V.G.Savchenko. Moscow, 2016, 419 p. (In Russ.).